This study evaluates the effectiveness of a yogurt enriched with bioactive lipids extracted from olive mill waste in platelet aggregation and other inflammatory and oxidative stress markers. The study will include three groups: the intervention group will receive the enriched yogurt while the other two groups will serve as controls (plain yogurt and no yogurt consumption).
Cardiovascular diseases are the leading cause of mortality worldwide. Data from the investigators research group indicate that platelet activating factor (PAF) is one of the most important inflammatory factors and the main mediator of thrombosis during the formation of atherosclerotic plaque. Thus, dietary interventions aimed at inhibition of PAF is of particular importance in public health level. The aim of the study is to examine the efficacy of administering in humans bioactive lipids extracted from olive mill waste (with proven in vitro anti-thrombotic activity and in vivo anti-atherosclerotic properties in rabbits fed an atherogenic diet) to inhibit the activity of PAF and other inflammatory mediators. Bioactive lipids are isolated by standardized methodology of oil manufacture byproducts. Preliminary studies have been done in animals to establish the safety of administration of these compounds and to clarify the effective dosages of administration for inhibiting formation of atherosclerotic plaques. The effectiveness of these compounds in humans will be examined in a randomized, double-blind clinical trial in subjects aged 40-60 years, lasting eight weeks. Supplementation with the bioactive lipids will be in the form of an enriched yogurt provided daily. The study includes three groups: treatment group, where enriched yogurt will be provided, plain yogurt treatment group and no consumption of yogurt group . Parameters that will be assessed are the inhibition of platelet aggregation (with three different stimuli, including PAF), lipid profile, inflammatory markers such as CRP, IL-6, TNFa, and oxidative stress markers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Enrollment
100
150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
150 g plain yogurt will be provided daily for 8 weeks
Harokopio University, Department of Nutrition and Dietetics
Athens, Attica, Greece
RECRUITINGChanges in Platelet aggregation
The ability of platelets to aggregate will be measured in platelet rich plasma (PRP) of volunteers using PAF, thrombin and ADP as aggregating factor.
Time frame: 0 (baseline), end of 4th week and 8th week
Changes in Blood lipid profile
Blood levels of cholesterol, LDL-cholesterol, HDL-cholesterol and triacylglycerols will be measured.
Time frame: 0 (baseline), end of 4th week and 8th week
Changes in Glucose and Insulin
Blood levels of glucose and insulin
Time frame: 0 (baseline), end of 4th week and 8th week
Changes in Gastro-intestinal symptoms
Gastro-intestinal symptoms and possible side effects from yogurt consumption will be assessed through validated questionnaires.
Time frame: 0 (baseline), end of 4th week and 8th week
Change in Dietary intake
Dietary intake will be assessed through two dietary recalls and a food frequency questionnaire at each time point.
Time frame: 0 (baseline), end of 8th week
Changes in Oxidative stress
Ex vivo serum oxidation as a marker for lipid oxidation and protein carbonyls as a marker for protein oxidation will be measured.
Time frame: 0 (baseline), end of 4th week and 8th week
Changes in Gut microbiota populations
the populations of lactobacilli, bifidobacteria and Clostridium histolyticum group will be estimated by real-time PCR using genus specific primers. Furthermore, the metabolic products of the gut microorganisms will be evaluated by measuring the short chain fatty acids profile in fecal samples.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 0 (baseline), end of 8th week
Changes in Inflammation-related markers
C-reactive protein (CRP), IL-6, TNFa, IL-10 levels in fasting blood samples.
Time frame: 0 (baseline), end of 4th week and 8th week